The FDA has approved Sanofi's teplizumab, sold as Tzield, for children with stage 3 diabetes, according to STAT News. The decision marks the first regulatory green light for the drug in this younger population, expanding its use beyond earlier-stage disease. However, the approval comes after an internal dispute between career FDA staff and the political appointee leading the Center for Drug Evaluation and Research (CDER).
The disagreement centered on the drug's risk-benefit profile, though specific details of the clash were not disclosed. This tension highlights ongoing friction within the agency over how to weigh efficacy against safety in vulnerable populations. The approval is significant for Sanofi, which acquired the drug through its purchase of Provention Bio in 2023.
No specific revenue projections or patient numbers were cited in the source. Teplizumab was previously approved in 2022 for delaying onset of type 1 diabetes in high-risk individuals, but this new indication targets children already diagnosed with stage 3 disease. The drug works by modulating the immune system to preserve insulin-producing beta cells.
The decision could reshape treatment paradigms for pediatric diabetes, potentially reducing long-term complications. However, the internal controversy may raise questions for clinicians about the robustness of the data. Sanofi faces the challenge of ensuring equitable access and managing supply chain logistics for this specialized therapy.
Some analysts have expressed caution about the drug's real-world effectiveness in children, though the source did not provide specific expert commentary. The approval also sets a precedent for how future pediatric autoimmune therapies might be evaluated at the FDA.